Perspective Therapeutics (CATX) Change in Accured Expenses (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Change in Accured Expenses data on file, last reported at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 40.8% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at $964000.0 (down 49.71% YoY), and the FY2025 full-year result was $2.0 million, down 44.14% from the prior year.
• Change in Accured Expenses slipped to -$3.6 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.5 million in Q3 2025 to a low of -$3.6 million in Q1 2026.
• A 5-year average of $337176.5 and a median of $17000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 3700.0% in 2022 and jumped 5958.82% in 2023, its largest moves.
• Tracing CATX's Change in Accured Expenses over 5 years: stood at $573000.0 in 2022, then jumped by 293.72% to $2.3 million in 2023, then soared by 42.38% to $3.2 million in 2024, then tumbled by 68.31% to $1.0 million in 2025, then tumbled by 454.91% to -$3.6 million in 2026.
• Business Quant data shows CATX's Change in Accured Expenses at -$3.6 million in Q1 2026, $1.0 million in Q4 2025, and $5.5 million in Q3 2025.